EUVIMEDEUVIMED entdecken
Crossref

Modulating G6PD/PGD to overcome FSP1/DHODH‐mediated ferroptosis defence: A novel oridonin derivative suppresses liver cancer

Chenhui Ma iD, Li Han, Hong Yao, Wenxuan Zhao, Feihong Chen, Xiuyuan Wu, Guoqi Li, Ruimin Huang, Cheng Heng Pang, Zheying Zhu, Jinyi Xu, Guoyu Pan iD

British Journal of Pharmacology · 2026-01 · 183 (2) · 249-267

DOI: 10.1111/bph.70160 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 27.08.2025. Verfasst von Chenhui Ma und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical and Environmental Engineering, University of Nottingham Ningbo China, Ningbo, China. Hauptthemen laut MEDLINE: Ferroptosis, Liver Neoplasms, Diterpenes, Kaurane, Carcinoma, Hepatocellular. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Chinese Academy of Sciences, China Pharmaceutical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatocellular carcinoma (HCC), a globally prevalent malignancy with high mortality rates, presents an unmet need for innovative effective therapies.

Purpose

This study aimed to explore the antitumour potential of compound XD, a novel oridonin derivative, on HCC and its underlying mechanism. Experimental Approach The antitumour effects of compound XD were investigated in several HCC cells lines and mice models. The mechanism of XD was investigated using FACS, qPCR, WB, ELISA, IHC, siRNA and plasmid transfection. Key Results Compound XD demonstrated potent inhibitory effects, surpassing sorafenib with a maximum of 10‐fold lower IC 50 values against HCC cell lines. Its anticancer activities were ferroptosis dependent, which could be attenuated by ferroptosis inhibitors including deferoxamine, ferrostatin‐1 and N ‐acetyl‐cysteine. Unlike sorafenib, XD decreased two pivotal regulator FSP1 and DHODH to induce ferroptosis, while their overexpression partially mitigated XD‐induced cytotoxicity and lipid peroxidation. In addition, XD treatment decreased cellular NADPH levels and inhibited the expression of G6PD and PGD in NADPH generation. Overexpression of G6PD or PGD reversed FSP1 and DHODH down‐regulation, rescuing the ferroptosis induced by XD. Bioinformation analysis indicated the significant up‐regulation of G6PD and PGD in clinical HCC patients and was positively correlated with cancer stages. Molecular docking and CETSA assay confirmed the binding capacity of XD with G6PD and PGD protein. Finally, XD dose‐dependently inhibited liver tumour growth and induced ferroptosis‐related markers in mice. Conclusion and Implications This study suggests XD as a potential ferroptosis inducer and the potential role of G6PD/PGD/FSP1/DHODH axis in governing ferroptosis sensitivity in HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisLiver NeoplasmsDiterpenes, KauraneCarcinoma, HepatocellularAntineoplastic AgentsHumansAnimalsMiceCell Line, TumorMaleMice, NudeMice, Inbred BALB C

Stichwörter der Autor:innen

FSP1 and DHODHG6PD and PGDferroptosisliver canceroridonin

Substanzen

Diterpenes, KauraneoridoninAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Chemical and Environmental Engineering, University of Nottingham Ningbo China, Ningbo, China.
  • Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
  • University of Chinese Academy of Sciences, Beijing, China.
  • State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, China.
  • Nanjing University of Chinese Medicine, Nanjing, China.
  • Division of Molecular Therapeutics & Formulation, School of Pharmacy, The University of Nottingham, University Park Campus, Nottingham, UK.

ORCID-Profile: Chenhui Ma, Guoyu Pan

Förderung

  • National Natural Science Foundation of China
  • Chinese Academy of Sciences
  • China Pharmaceutical University
  • University of Nottingham Ningbo China

Zitieren

APA

Ma, C., Han, L., Yao, H., Zhao, W., Chen, F., Wu, X., Li, G., Huang, R., Pang, C. H., Zhu, Z., Xu, J., & Pan, G. (2026). Modulating G6PD/PGD to overcome FSP1/DHODH‐mediated ferroptosis defence: A novel oridonin derivative suppresses liver cancer. British Journal of Pharmacology, 183(2), 249-267. https://doi.org/10.1111/bph.70160

Vancouver

Ma C, Han L, Yao H, Zhao W, Chen F, Wu X, et al. Modulating G6PD/PGD to overcome FSP1/DHODH‐mediated ferroptosis defence: A novel oridonin derivative suppresses liver cancer. British Journal of Pharmacology. 2026;183(2):249-267. doi:10.1111/bph.70160

BibTeX
@article{Ma2026,
  author = {Ma, Chenhui and Han, Li and Yao, Hong and Zhao, Wenxuan and Chen, Feihong and Wu, Xiuyuan and Li, Guoqi and Huang, Ruimin and Pang, Cheng Heng and Zhu, Zheying and Xu, Jinyi and Pan, Guoyu},
  title = {Modulating G6PD/PGD to overcome FSP1/DHODH‐mediated ferroptosis defence: A novel oridonin derivative suppresses liver cancer},
  journal = {British Journal of Pharmacology},
  year = {2026},
  volume = {183},
  number = {2},
  pages = {249--267},
  doi = {10.1111/bph.70160}
}
Kostenlos starten →